Combioxin SA, a Geneva-based startup developing a non-antibiotic drug to trap and neutralize bacterial toxins, has successfully shown initial safety and efficacy for the therapy, CAL-02, in a phase I study of patients with severe community-acquired pneumococcal pneumonia taking the experimental therapy along with an antibiotic.